Diartis Pharmaceuticals is a biotechnology company developing therapeutic proteins for the treatment of metabolic diseases. Diartis Pharmaceuticals is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN.
Glucagon-like peptide-1 analog
Type 2 diabetes
Phase 1 clinical trials in patients with T2DM (enrollment completed)
Diartis Pharmaceuticals is developing products for metabolic disease. The company is interested in exploring partnerships on these products to accelerate the development process and ensure successful commercialization.
Diartis Pharmaceuticals, Inc.
275 Shoreline Drive, Suite 450
Redwood City, CA 94065
(650) 963 8595